JP2021513323A5 - - Google Patents
Info
- Publication number
- JP2021513323A5 JP2021513323A5 JP2020533287A JP2020533287A JP2021513323A5 JP 2021513323 A5 JP2021513323 A5 JP 2021513323A5 JP 2020533287 A JP2020533287 A JP 2020533287A JP 2020533287 A JP2020533287 A JP 2020533287A JP 2021513323 A5 JP2021513323 A5 JP 2021513323A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023188151A JP2024009004A (ja) | 2018-02-09 | 2023-11-02 | Ｃ－ｋｉｔ抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1802201.2 | 2018-02-09 | ||
| GBGB1802201.2A GB201802201D0 (en) | 2018-02-09 | 2018-02-09 | Binding agents |
| GB1806468.3 | 2018-04-20 | ||
| GBGB1806468.3A GB201806468D0 (en) | 2018-02-09 | 2018-04-20 | C-KIT Binding agents |
| PCT/EP2019/053331 WO2019155067A1 (en) | 2018-02-09 | 2019-02-11 | C-kit antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188151A Division JP2024009004A (ja) | 2018-02-09 | 2023-11-02 | Ｃ－ｋｉｔ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513323A JP2021513323A (ja) | 2021-05-27 |
| JP2021513323A5 true JP2021513323A5 (https=) | 2023-05-16 |
| JP7449861B2 JP7449861B2 (ja) | 2024-03-14 |
Family
ID=61731463
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533287A Active JP7449861B2 (ja) | 2018-02-09 | 2019-02-11 | Ｃ－ｋｉｔ抗体 |
| JP2023188151A Pending JP2024009004A (ja) | 2018-02-09 | 2023-11-02 | Ｃ－ｋｉｔ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188151A Pending JP2024009004A (ja) | 2018-02-09 | 2023-11-02 | Ｃ－ｋｉｔ抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10611838B2 (https=) |
| EP (1) | EP3749694A1 (https=) |
| JP (2) | JP7449861B2 (https=) |
| CN (2) | CN111683970B (https=) |
| AU (2) | AU2019219312B2 (https=) |
| CA (1) | CA3085246A1 (https=) |
| GB (2) | GB201802201D0 (https=) |
| IL (1) | IL275657B1 (https=) |
| SG (1) | SG11202005357QA (https=) |
| WO (1) | WO2019155067A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201802201D0 (en) | 2018-02-09 | 2018-03-28 | Ultrahuman Five Ltd | Binding agents |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| KR102772859B1 (ko) * | 2019-11-25 | 2025-02-27 | 주식회사 노벨티노빌리티 | c-kit에 대한 항체 및 이의 용도 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US20240117057A1 (en) * | 2021-01-22 | 2024-04-11 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4486784A1 (en) * | 2022-03-01 | 2025-01-08 | CSL Innovation Pty Ltd | Methods of bone marrow conditioning |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| JP2025524370A (ja) * | 2022-06-09 | 2025-07-30 | サンタ アナ バイオ インコーポレイテッド | ｃ－Ｋｉｔ及び／またはｓｉｇｌｅｃを標的とする抗体ならびにその使用 |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| CN119948057A (zh) * | 2022-07-28 | 2025-05-06 | 微粒疗法有限公司 | 双特异性抗C-Kit和抗CD203c抗原结合分子及其用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026008055A1 (zh) * | 2024-07-05 | 2026-01-08 | 江苏恒瑞医药股份有限公司 | 抗kit抗体及其医药用途 |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2600929A1 (en) | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
| MX2008015830A (es) | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| CN103620032B (zh) | 2010-12-31 | 2016-02-24 | 生物蛋白有限公司 | 抗体的快速人源化 |
| US9540443B2 (en) | 2011-01-26 | 2017-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| ES2701051T3 (es) | 2013-03-15 | 2019-02-20 | Novartis Ag | Conjugados de anticuerpo-fármaco |
| WO2015050959A1 (en) * | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| JP6441949B6 (ja) * | 2013-11-05 | 2019-01-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ヒト中和抗ｋｉｔ抗体及びその使用 |
| US10550196B2 (en) | 2014-04-27 | 2020-02-04 | Famewave Ltd. | Humanized antibodies against CEACAM1 |
| WO2016020791A1 (en) * | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| GB201802201D0 (en) | 2018-02-09 | 2018-03-28 | Ultrahuman Five Ltd | Binding agents |
-
2018
- 2018-02-09 GB GBGB1802201.2A patent/GB201802201D0/en not_active Ceased
- 2018-04-20 GB GBGB1806468.3A patent/GB201806468D0/en not_active Ceased
-
2019
- 2019-02-11 JP JP2020533287A patent/JP7449861B2/ja active Active
- 2019-02-11 EP EP19706418.1A patent/EP3749694A1/en active Pending
- 2019-02-11 SG SG11202005357QA patent/SG11202005357QA/en unknown
- 2019-02-11 CA CA3085246A patent/CA3085246A1/en active Pending
- 2019-02-11 CN CN201980011298.7A patent/CN111683970B/zh active Active
- 2019-02-11 WO PCT/EP2019/053331 patent/WO2019155067A1/en not_active Ceased
- 2019-02-11 CN CN202311493358.8A patent/CN117510635A/zh active Pending
- 2019-02-11 AU AU2019219312A patent/AU2019219312B2/en active Active
- 2019-07-25 US US16/521,793 patent/US10611838B2/en active Active
-
2020
- 2020-03-13 US US16/818,149 patent/US11377493B2/en active Active
- 2020-06-25 IL IL275657A patent/IL275657B1/en unknown
-
2022
- 2022-07-01 US US17/810,423 patent/US12173067B2/en active Active
-
2023
- 2023-10-17 AU AU2023251427A patent/AU2023251427A1/en active Pending
- 2023-11-02 JP JP2023188151A patent/JP2024009004A/ja active Pending
-
2024
- 2024-11-13 US US18/946,389 patent/US20250066475A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513323A5 (https=) | ||
| JP2021519100A5 (https=) | ||
| JP2021515541A5 (https=) | ||
| RU2020109544A (ru) | Связывающие агенты | |
| JP2021516537A5 (https=) | ||
| JP2025000787A5 (https=) | ||
| JP2020531048A5 (https=) | ||
| JP2021515542A5 (https=) | ||
| US20240239890A1 (en) | Cytotoxicity-inducing therapeutic agent | |
| JP2024513921A5 (https=) | ||
| JP2024116190A (ja) | 抗ｃｄ３抗体及びその使用 | |
| KR102078292B1 (ko) | 신규한 항 c-Met 항체 및 이의 용도 | |
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2017149720A5 (https=) | ||
| JP2021515544A5 (https=) | ||
| JP2022553908A5 (https=) | ||
| JP2025503322A5 (https=) | ||
| CN105384818B (zh) | 抗人Delta like 4单克隆抗体及其应用 | |
| JP2020514277A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2023525495A5 (https=) | ||
| RU2019125975A (ru) | Связывающие агенты | |
| HRP20250523T1 (hr) | Pd1 i vegfr2 sredstva za dvostruko vezivanje | |
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| JP2024540148A5 (https=) |